Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type
- PMID: 15041722
- DOI: 10.1158/1078-0432.ccr-03-1061
Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type
Abstract
Purpose: BRCA1-related breast cancers are more frequently estrogen receptor (ER) negative than are either BRCA2-related or nonhereditary breast cancers. The relationship between ER status and other clinical features of hereditary breast cancers has not been well studied.
Experimental design: ER status, grade, and histological tumor type were evaluated in 1131 women with invasive breast cancer, ascertained at 10 centers in North America. There were 208 BRCA1 mutation carriers, 88 BRCA2 carriers, and 804 women without a known mutation. We stratified the patients by mutation status, grade, age, and histological type and calculated the percentage of ER-positive tumors within each stratum.
Results: BRCA1 mutation carriers were more likely to have ER-negative breast cancers than were women in other groups, after adjustment for age, grade, and histological subtype (P < 0.001). Only 3.9% of BRCA1-related breast cancers were ER-positive cancers occurring in women in their postmenopausal years. The direction and magnitude of the change in ER status with increasing age at diagnosis in BRCA1 carriers was significantly different from in BRCA2 carriers (P(intercept) = 0.0002, P(slope) = 0.04). Notably, changes in ER status with age at diagnosis for BRCA1 carriers and noncarriers were almost identical (P(slope) = 0.98).
Conclusions: The strong relationship between the presence of a BRCA1 mutation and the ER-negative status of the breast cancers is neither a consequence of the young age at onset nor the high grade but is an intrinsic property of BRCA1-related cancers. The ER-negative status of these cancers may reflect the cell of origin of BRCA1-related cancers.
Similar articles
-
Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.Breast Cancer Res Treat. 2017 Jun;163(3):565-571. doi: 10.1007/s10549-017-4198-4. Epub 2017 Mar 25. Breast Cancer Res Treat. 2017. PMID: 28343309 Free PMC article.
-
BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.Mol Genet Genomic Med. 2019 Mar;7(3):e493. doi: 10.1002/mgg3.493. Epub 2019 Jan 16. Mol Genet Genomic Med. 2019. PMID: 30652428 Free PMC article.
-
Incorporating tumour pathology information into breast cancer risk prediction algorithms.Breast Cancer Res. 2010;12(3):R28. doi: 10.1186/bcr2576. Epub 2010 May 18. Breast Cancer Res. 2010. PMID: 20482762 Free PMC article.
-
The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications.Mod Pathol. 2005 Oct;18(10):1305-20. doi: 10.1038/modpathol.3800453. Mod Pathol. 2005. PMID: 15933754 Review.
-
Breast cancer surveillance in women with hereditary risk due to BRCA1 or BRCA2 mutations.Clin Breast Cancer. 2004 Oct;5(4):260-8; discussion 269-71. doi: 10.3816/cbc.2004.n.029. Clin Breast Cancer. 2004. PMID: 15507170 Review.
Cited by
-
FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer.EMBO Mol Med. 2024 Aug;16(8):1957-1980. doi: 10.1038/s44321-024-00094-2. Epub 2024 Jul 2. EMBO Mol Med. 2024. PMID: 38956205 Free PMC article.
-
Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancers.BMC Cancer. 2009 Oct 10;9:360. doi: 10.1186/1471-2407-9-360. BMC Cancer. 2009. PMID: 19818148 Free PMC article.
-
Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC).Clin Transl Oncol. 2014 Mar;16(3):280-4. doi: 10.1007/s12094-013-1070-9. Epub 2013 Aug 27. Clin Transl Oncol. 2014. PMID: 23982851
-
Lower mitotic activity in BRCA1/2-associated primary breast cancers occurring after risk-reducing salpingo-oophorectomy.Cancer Biol Ther. 2014 Apr;15(4):371-9. doi: 10.4161/cbt.27628. Epub 2014 Jan 14. Cancer Biol Ther. 2014. PMID: 24423863 Free PMC article.
-
Basal phenotype in breast carcinoma occurring in women aged 35 or younger.Pathol Oncol Res. 2009 Mar;15(1):41-5. doi: 10.1007/s12253-008-9090-4. Epub 2008 Aug 28. Pathol Oncol Res. 2009. PMID: 18752048
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous